Liquidia (NASDAQ:LQDA) Director Sells $6,076,829.28 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 85,062 shares of Liquidia stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $71.44, for a total transaction of $6,076,829.28. Following the completion of the transaction, the director directly owned 980,073 shares in the company, valued at approximately $70,016,415.12. The trade was a 7.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Down 5.4%

LQDA traded down $3.88 during trading on Tuesday, reaching $67.92. The company had a trading volume of 2,323,237 shares, compared to its average volume of 1,746,808. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $73.22. The business’s fifty day moving average price is $50.54 and its 200 day moving average price is $41.24. The company has a market cap of $6.04 billion, a P/E ratio of 485.18 and a beta of 0.57.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The company’s revenue was up 4187.1% on a year-over-year basis. Equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the fourth quarter worth $25,000. NewEdge Advisors LLC bought a new stake in Liquidia during the second quarter worth $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Liquidia during the third quarter worth $30,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the third quarter worth $34,000. Finally, Covestor Ltd raised its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LQDA shares. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Needham & Company LLC boosted their price objective on shares of Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Raymond James Financial reissued a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Oppenheimer set a $75.00 price objective on shares of Liquidia in a research report on Friday, June 5th. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $60.29.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).